Literature DB >> 11469476

Growth hormone, insulin, and insulin-like growth factor-1 in hypermobility syndrome.

C W Denko1, B Boja.   

Abstract

OBJECTIVE: To investigate growth factors in patients with hypermobility syndrome (HMS), namely insulin, insulin-like growth factor-1 (IGF-1), and growth hormone (GH).
METHODS: Standard radioimmunoassay quantified serum levels of insulin, IGF-1, and GH in 24 women and 7 men with HMS, and in suitable age and sex matched controls. Several patients with other heritable connective disorders were also studied, including congenital hip dysplasia and severe kyphosis.
RESULTS: Patients with HMS and with otherwise unexplained joint and muscle pain were found to have elevated levels of insulin, IGF-1, and GH. Patients with heritable connective tissue disorders had elevated GH levels, and several patients had elevated insulin and IGF-1 levels.
CONCLUSION: In patients with HMS, elevation of serum growth factors helps establish the diagnosis. GH alone can induce muscle and joint pain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469476

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome.

Authors:  Charles W Denko; Charles J Malemud
Journal:  Rheumatol Int       Date:  2004-07-24       Impact factor: 2.631

Review 2.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 3.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Pain Headache Rep       Date:  2005-10

4.  Age-related changes in serum growth hormone, insulin-like growth factor-1 and somatostatin in system lupus erythematosus.

Authors:  Charles W Denko; Charles J Malemud
Journal:  BMC Musculoskelet Disord       Date:  2004-10-20       Impact factor: 2.362

5.  Serum prolidase activity in benign joint hypermobility syndrome.

Authors:  Serda Em; Demet Ucar; Pelin Oktayoglu; Mehtap Bozkurt; Mehmet Caglayan; Ismail Yıldız; Osman Evliyaoglu; Kemal Nas
Journal:  BMC Musculoskelet Disord       Date:  2014-03-11       Impact factor: 2.362

6.  Hypermobility in individuals with Kabuki syndrome: The effect of growth hormone treatment.

Authors:  Dina A Schott; Constance T R M Stumpel; Merel Klaassens
Journal:  Am J Med Genet A       Date:  2018-12-17       Impact factor: 2.802

Review 7.  The epidemiology and demographics of hip dysplasia.

Authors:  Randall T Loder; Elaine N Skopelja
Journal:  ISRN Orthop       Date:  2011-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.